Head of Research and Development · Neumora Therapeutics, Inc. (NMRA)

Rob Lenz

FY2023 is the first fiscal year CompBrief holds for Rob Lenz as a named executive officer of Neumora Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$13,582,881

Salary $169,231Stock awards $6,009,350Bonus $504,201

2nd of 4 named executive officers at Neumora Therapeutics by FY2023 total.

4 named officers on file for Neumora Therapeutics, FY2023

Rob Lenz’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Neumora Therapeutics’s whole pay program stands against its peers

  • Neumora Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NMRA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A).

Free

Get Rob Lenz’s full pay file as a PDF — free

More than this page: up to 10 years of Rob’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Rob Lenz compensation by year

Neumora Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Neumora Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$169,231
Bonus$504,201
Stock awards$6,009,350
Option awards$6,803,239
Non-equity incentive$96,632
Pension and deferred compensation$0
All other$228
Total$13,582,881

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Neumora Therapeutics, Inc. DEF 14A filed April 25, 2024, accession 0000950170-24-048287, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Neumora Therapeutics, Inc. filed document, accession 0000950170-24-048287. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU352,941$6,017,644—
Option502,934—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Neumora Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Neumora Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Henry GosebruchPresident and Chief Executive Officer$21,999,269
Rob Lenz · this pageHead of Research and Development$13,582,881
Paul BernsExecutive Chairman and former Chief Executive Officer$8,570,268
Jason DuncanChief Legal Officer$4,119,980

The full Neumora Therapeutics compensation record

free company brief

This page is one person within Neumora Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Neumora Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rob Lenz's compensation dossier · One-time report. No refunds.